| Filed On | Filing |
|---|---|
| 03 Jul 2017 |
8-K/A: Financial Statements and Exhibits
On April 20, 2017, PTC Therapeutics, Inc. ("PTC" or the “Company”) completed its acquisition of all rights to EMFLAZA™ (deflazacort) (the “Transaction”) pursuant to an asset purchase agreement (the "Asset Purchase Agreement"), dated Marc... |
| 30 Jun 2017 |
8-K/A: Regulation FD Disclosure
Accessing EMFLAZA™ (deflazacort) for Duchenne muscular Dystrophy PPMD 2017 Connect Conference June 29, 2017; 4:00pm Stuart Peltz, PhD PTC Therapeutics, South Plainfield, NJ |
| 23 Mar 2016 |
8-K/A: Costs Associated with Exit or Disposal Activities
On March 18, 2016, PTC Therapeutics, Inc. (the “Company”) committed to a reduction in workforce of approximately 18%, which will primarily affect employees and contractors in the U.S. The reduction in workforce is part of the Company’s p... |
Loading...